Which of the following is true about Repaglinide?
Ans. is 'd' i.e., It should be avoided in patients with liver diseasesRef: KDT 7/e p. 2731Repaglinide:This meglitinide analogue oral hypoglycaemic is designed to normalise mealtime glucose excursions.Though not a sulfonylurea, it acts in an analogous manner by binding to SUR closure of ATP dependent K+ channels depolarisation insulin release.Repaglinide is indicated only in selected type 2 diabetics who suffer pronounced postprandial hyperglycaemia, or to supplement metformin/long-acting insulin.It should be avoided in liver disease,
It belongs to sulfonylurea class of drugs
It is not well absorbed on oral administration
It is used to control sleep time hyperglycemia
It should be avoided in patients with liver diseases